Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy.
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada.
Victor H
VH
Jimenez-Zepeda
Suzanne
S
Trudel
Andrew
A
Winter
Donna E
DE
Reece
Christine
C
Chen
Vishal
V
Kukreti
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007147:Immunoglobulin Light Chains; D008297:Male; D010265:Paraproteinemias / Q000401:mortality / Q000628:therapy*; D011719:Pyrazines / Q000008:administration & dosage*; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D015996:Survival Rate; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents; D001897:Boronic Acids; D007147:Immunoglobulin Light Chains; D011719:Pyrazines; D000069286:Bortezomib